{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T09:00:23Z","timestamp":1780909223452,"version":"3.54.1"},"reference-count":56,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>Research in multiple myeloma increasingly relies on surrogate end\u2010points to expedite approvals, yet these may not reflect patient priorities. We conducted a mixed\u2010methods study to identify outcomes valued by patients and clinicians and compare them with end\u2010points used in randomized controlled trials (RCTs). Interviews with 10 patients and 6 clinicians identified treatment priorities, which, together with end\u2010points from a systematic review of myeloma RCTs, informed tailored surveys, completed by 117 patients and 105 clinicians. Both groups ranked quality of life (QoL) as most important (odds ratio [OR] 1.01; 95% confidence interval [CI] 0.55\u20131.87). Clinicians more often prioritized overall survival (OS) (OR 1.92; 95% CI 1.05\u20133.50) and progression\u2010free survival (PFS) (OR 5.37; 95% CI 1.95\u201314.79), whereas patients prioritized pain reduction (OR 0.03; 95% CI 0.00\u20130.23). Compared with RCT end\u2010points, patients emphasized QoL (OR 0.03; 95% CI 0.01\u20130.07) and pain elimination (OR 0.05; 95% CI 0.02\u20130.11), while trials favoured PFS (OR 6.33; 95% CI 2.53\u201315.83) and response (OR 17.75; 95% CI 5.56\u201356.61). Clinicians aligned with trials on PFS but valued QoL and OS more highly. QoL emerged as a shared priority, underscoring the need for patient\u2010centred trial designs that better capture outcomes meaningful to those living with myeloma.<\/jats:p>","DOI":"10.1111\/bjh.70396","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T04:54:37Z","timestamp":1773032077000},"page":"1650-1659","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Patients', clinicians' and research's priorities on important outcomes in multiple myeloma: A mixed\u2010methods study"],"prefix":"10.1111","volume":"208","author":[{"given":"Maria","family":"Mainou","sequence":"first","affiliation":[{"name":"Clinical Research and Evidence\u2010Based Medicine Unit, Second Medical Department Aristotle University of Thessaloniki, Hippokration General Hospital  Thessaloniki Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Karagiannis","sequence":"additional","affiliation":[{"name":"Clinical Research and Evidence\u2010Based Medicine Unit, Second Medical Department Aristotle University of Thessaloniki, Hippokration General Hospital  Thessaloniki Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eirini","family":"Pagkalidou","sequence":"additional","affiliation":[{"name":"Department of Hygiene, Social\u2010Preventive Medicine &amp; Medical Statistics, School of Medicine, Faculty of Health Sciences Aristotle University of Thessaloniki  Thessaloniki Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aris","family":"Liakos","sequence":"additional","affiliation":[{"name":"Clinical Research and Evidence\u2010Based Medicine Unit, Second Medical Department Aristotle University of Thessaloniki, Hippokration General Hospital  Thessaloniki Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis","family":"Malandrakis","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics, School of Medicine National and Kapodistrian University of Athens  Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evdoxia","family":"Hatjiharissi","sequence":"additional","affiliation":[{"name":"Hematology Unit, First Department of Internal Medicine, AHEPA General Hospital Aristotle University of Thessaloniki  Thessaloniki Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Chissan","sequence":"additional","affiliation":[{"name":"Second Propedeutic Department of Internal Medicine Aristotle University of Thessaloniki, Hippokration General Hospital  Thessaloniki Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0223-185X","authenticated-orcid":false,"given":"Evdokia","family":"Mandala","sequence":"additional","affiliation":[{"name":"Fourth Medical Department Aristotle University of Thessaloniki  Thessaloniki Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Van Oekelen","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology Icahn School of Medicine at Mount Sinai  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efthymia","family":"Vlachaki","sequence":"additional","affiliation":[{"name":"Second Department of Internal Medicine Aristotle University of Thessaloniki, Hippokration General Hospital  Thessaloniki Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Papaioannou","sequence":"additional","affiliation":[{"name":"Hematology Unit, First Department of Internal Medicine, AHEPA General Hospital Aristotle University of Thessaloniki  Thessaloniki Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelos","family":"Terpos","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics, School of Medicine National and Kapodistrian University of Athens  Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6464-783X","authenticated-orcid":false,"given":"Ghulam Rehman","family":"Mohyuddin","sequence":"additional","affiliation":[{"name":"Division of Hematology University of Utah, Huntsman Cancer Institute  Salt Lake City Utah USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apostolos","family":"Tsapas","sequence":"additional","affiliation":[{"name":"Clinical Research and Evidence\u2010Based Medicine Unit, Second Medical Department Aristotle University of Thessaloniki  Thessaloniki Greece"},{"name":"Harris Manchester College, University of Oxford  Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,2,26]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-116129"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27422"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104529"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26166"},{"key":"e_1_2_13_6_1","unstructured":"Meeting ODACO.Drug topic: use of minimal residual disease (MRD) as an endpoint in multiple myeloma clinical trials.2024. April 12 2024."},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-018-4137-x"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1353\/book.74312"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11606\u2010019\u201005608\u20100"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.314.7094.1580"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.zefq.2016.01.005"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40900-022-00350-0"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1109283"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2015.1354"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pec.2015.06.022"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003044"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0615"},{"issue":"3","key":"e_1_2_13_18_1","article-title":"Development of a patient centered outcome set for patients with multiple myeloma to be used in clinical practice","volume":"4","author":"Oerlemans S","year":"2020","journal-title":"Hema"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-299487"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-017-1978-4"},{"issue":"2","key":"e_1_2_13_21_1","first-page":"E64","article-title":"Patients' experiences with multiple myeloma: a meta\u2010aggregation of qualitative studies","volume":"44","author":"Hauksdottir B","year":"2017","journal-title":"Oncol Nurs Forum"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-14-496"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28340"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2009.01303.x"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-010-0218-6"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-015-1261-6"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12012"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.05.003"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare12161660"},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.1136\/eb-2016-102306"},{"key":"e_1_2_13_31_1","volume-title":"Designing and conducting mixed methods research","author":"Creswell JW","year":"2018"},{"key":"e_1_2_13_32_1","doi-asserted-by":"publisher","DOI":"10.1258\/jhsrp.2007.007074"},{"key":"e_1_2_13_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10488-013-0528-y"},{"key":"e_1_2_13_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cptl.2018.03.019"},{"key":"e_1_2_13_35_1","unstructured":"ECIS\u2014European Cancer Information System.Estimates of prevalence by country and cancer site [Internet].2025. \u00a9 European Union. Available from:https:\/\/ecis.jrc.ec.europa.eu"},{"key":"e_1_2_13_36_1","volume-title":"RStudio: integrated development for R","author":"R Team","year":"2020"},{"key":"e_1_2_13_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.72"},{"key":"e_1_2_13_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01109-4"},{"key":"e_1_2_13_39_1","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6963-6-28"},{"key":"e_1_2_13_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18568"},{"key":"e_1_2_13_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00750-1"},{"key":"e_1_2_13_42_1","doi-asserted-by":"publisher","DOI":"10.1200\/OP\u201025\u201000322"},{"key":"e_1_2_13_43_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-5467-x"},{"key":"e_1_2_13_44_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.127860"},{"key":"e_1_2_13_45_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.0363"},{"key":"e_1_2_13_46_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00432-4"},{"key":"e_1_2_13_47_1","doi-asserted-by":"publisher","DOI":"10.1017\/S026646232000207X"},{"key":"e_1_2_13_48_1","doi-asserted-by":"publisher","DOI":"10.1370\/afm.2042"},{"key":"e_1_2_13_49_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-157549"},{"key":"e_1_2_13_50_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40900-023-00476-9"},{"key":"e_1_2_13_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00319-4"},{"key":"e_1_2_13_52_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1628121"},{"key":"e_1_2_13_53_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-180951"},{"key":"e_1_2_13_54_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.4322"},{"key":"e_1_2_13_55_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S474722"},{"key":"e_1_2_13_56_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00543-y"},{"key":"e_1_2_13_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00451-0"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.70396","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjh.70396","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.70396","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T08:11:27Z","timestamp":1780906287000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.70396"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,26]]},"references-count":56,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1111\/bjh.70396"],"URL":"https:\/\/doi.org\/10.1111\/bjh.70396","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,26]]},"assertion":[{"value":"2025-10-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}